Pemigatinib (Pemazyre®) for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement. Update May 2021

Grössmann, N. (2021): Pemigatinib (Pemazyre®) for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement. Update May 2021. Oncology Fact Sheet Nr. 40.

[thumbnail of Oncology Fact Sheet Nr.40_Update.pdf]

Preview

PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader
99kB

Item Type:	Horizon Scanning of Medicines
Subjects:	QV Pharmacology, toxicology, pharmacy > QV 60-370 Pharmacology QZ Pathology > QZ 200-380 Neoplasms.Cysts WB Practice of medicine > WB 300-962 Therapeutics WI Digestive system > WI 700-770 Liver. Billary tract
Language:	English
Series Name:	Oncology Fact Sheet Nr. 40
Deposited on:	22 Feb 2021 13:12
Last Modified:	10 Jul 2025 11:31

Repository Staff Only: item control page